News

June 3, 2020

Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract

BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at $1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals.

May 18, 2020

Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.

May 14, 2020

Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome

Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).

April 21, 2020

Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire’s next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.

January 15, 2020

Cellphire Awarded $29.25 Million U.S. Army Cryopreserved Platelet Development Contract

Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 6.5-year contract valued at $29.25 million (including all options) to develop a U.S. Food and Drug Administration (FDA) licensed dimethyl sulfoxide (DMSO) Cryopreserved Platelets (CPP) product.

October 24, 2019

Transfusion News – Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial

Transfusion News

July 18, 2019

Cellphire Completes Enrollment of Phase 1 Clinical Trial of Thrombosomes®

Cellphire, Inc., the global leader in long-term cell stabilization and storage of platelets, announced today that the company completed enrollment of its Phase 1 clinical trial to evaluate Thrombosomes® in bleeding, thrombocytopenic patients. Thrombosomes is a freeze-dried hemostatic agent derived from human platelets.

May 15, 2019

John B. Holcomb, M.D., F.A.C.S., Joins Cellphire as Medical Consultant

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that John B. Holcomb, M.D., F.A.C.S., will serve as Medical Consultant.